{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:16:18Z","timestamp":1781525778689,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BSRBR-AS"},{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AbbVie and UCB"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Whether comorbidities influence disease activity assessment in axial SpA (axSpA) is unclear. Comorbidities inflate DAS28 in rheumatoid arthritis through the patient global score. We examined whether axSpA disease activity measures are differentially affected, and whether comorbidities inflate the AS disease activity score (ASDAS) through the patient global component.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used baseline data from the British Society for Rheumatology Biologics Register for AS, including 14 physician diagnosed comorbidities. Linear models were used to compare disease activity (BASDAI, spinal pain, ASDAS) and ESR\/CRP according to comorbidity count, adjusted for age, gender, BMI, smoking, socioeconomic status, and education. The same models were used to examine whether the patient global score was associated with comorbidities, additionally adjusting for other ASDAS components.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The number of participants eligible for analysis was 2043 (67% male, mean age 49\u2009years); 44% had at least one comorbidity. Each additional comorbidity was associated with higher BASDAI by 0.40\u2009units (95% CI: 0.27, 0.52) and spinal pain by 0.53 (95% CI: 0.37, 0.68). Effect size for ASDAS (0.09\u2009units; 95% CI: 0.03, 0.15) was not clinically significant. ESR and CRP were not associated with comorbidity count. Depression, heart failure and peptic ulcer were consistently associated with higher disease activity measures, but not CRP\/ESR. Patient global was associated with comorbidity count, but not independently of other ASDAS components (P\u2009=\u20090.75).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Comorbidities were associated with higher patient reported disease activity in axSpA. Clinicians should be mindful of the potential impact of comorbidities on patient reported outcome measures and consider additionally collecting ASDAS when comorbidities are present.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa768","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T20:14:54Z","timestamp":1604952894000},"page":"3189-3198","source":"Crossref","is-referenced-by-count":30,"title":["Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"first","affiliation":[{"name":"Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK"},{"name":"Department of Rheumatology, Liverpool University Hospitals, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T","family":"Jones","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), School of Medicine Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-3314","authenticated-orcid":false,"given":"Gary J","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), School of Medicine Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-6211","authenticated-orcid":false,"given":"Robert J","family":"Moots","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Liverpool University Hospitals, Liverpool, UK"},{"name":"Faculty of Health, Social Care and Medicine, Edge Hill University, Ormskirk, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Goodson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Liverpool University Hospitals, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2021070122133231300_keaa768-B1","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"2021070122133231300_keaa768-B2","first-page":"980","article-title":"Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol"},{"key":"2021070122133231300_keaa768-B3"},{"key":"2021070122133231300_keaa768-B4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/keh595","article-title":"Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives","volume":"44","author":"Spoorenberg","year":"2005","journal-title":"Rheumatology"},{"key":"2021070122133231300_keaa768-B5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/acr.23468","article-title":"Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the assessment of spondyloarthritis international society comorbidities in spondyloarthritis study","volume":"70","author":"Nikiphorou","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2021070122133231300_keaa768-B6","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/rheumatology\/key224","article-title":"The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank","volume":"57","author":"Cook","year":"2018","journal-title":"Rheumatology"},{"key":"2021070122133231300_keaa768-B7","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.40185","article-title":"Co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK National register","volume":"69","author":"Macfarlane","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021070122133231300_keaa768-B8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021070122133231300_keaa768-B9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021070122133231300_keaa768-B10","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021070122133231300_keaa768-B11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/art.39988","article-title":"Different rating of global rheumatoid arthritis disease activity in rheumatoid arthritis patients with multiple morbidities","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021070122133231300_keaa768-B12","doi-asserted-by":"crossref","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","article-title":"Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Zhao","year":"2020","journal-title":"Rheumatology"},{"key":"2021070122133231300_keaa768-B13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070122133231300_keaa768-B14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12891-015-0805-x","article-title":"The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment","volume":"16","author":"Macfarlane","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2021070122133231300_keaa768-B15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/rheumatology\/key371","article-title":"Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS)","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology"},{"key":"2021070122133231300_keaa768-B16","author":"Stolwijk","year":"2015"},{"issue":"4 Suppl 55","key":"2021070122133231300_keaa768-B17","first-page":"S56","article-title":"Extra-articular manifestations","volume":"27","author":"Mielants","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2021070122133231300_keaa768-B18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/occmed\/kqu168","article-title":"The Chalder fatigue scale (CFQ 11)","volume":"65","author":"Jackson","year":"2015","journal-title":"Occup Med Lond"},{"issue":"Suppl 11","key":"2021070122133231300_keaa768-B19","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"Suppl 10","key":"2021070122133231300_keaa768-B20","article-title":"Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) [abstract","volume":"70","author":"Richard","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021070122133231300_keaa768-B21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/acr.21747","article-title":"Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study","volume":"64","author":"Tubach","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2021070122133231300_keaa768-B22","first-page":"80","article-title":"Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study","volume":"32","author":"Pavy","year":"2005","journal-title":"J Rheumatol"},{"key":"2021070122133231300_keaa768-B23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12874-016-0167-6","article-title":"Minimal important differences for fatigue patient reported outcome measures\u2014a systematic review","volume":"16","author":"Nordin","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2021070122133231300_keaa768-B24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1513\/AnnalsATS.201808-564PS","article-title":"Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals","volume":"16","author":"Lederer","year":"2018","journal-title":". Ann Am Thorac Soc"},{"key":"2021070122133231300_keaa768-B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-1353-0","volume-title":"Regression methods in biostatistics: linear, logistic, survival, and repeated measures models","author":"Vittinghoff","year":"2012","edition":"2nd edn"},{"key":"2021070122133231300_keaa768-B26","first-page":"524","article-title":"CEM: coarsened exact matching in Stata","volume-title":"Stata J","author":"Blackwell","year":"2009"},{"key":"2021070122133231300_keaa768-B27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature","volume":"18","author":"Nikiphorou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021070122133231300_keaa768-B28","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","article-title":"Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS","volume":"59","author":"Macfarlane","year":"2020","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3189\/38849901\/keaa768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3189\/38849901\/keaa768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T22:14:59Z","timestamp":1625177699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/7\/3189\/6040714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa768","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,17]]}}}